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Abstract: Zeolitic imidazolate framework (ZIF) biocompo-
sites show the capacity to protect and deliver biotherapeutics.
To date, the progress in this research area is based on
laboratory batch methods. Now, the first continuous flow
synthetic method is presented for the encapsulation of a model
protein (bovine serum albumin, BSA) and a clinical therapeu-
tic (a1-antitrypsin, AAT) in ZIF-8. The in situ kinetics of
nucleation, growth, and crystallization of BSA@ZIF-8 were
studied by small-angle X-ray scattering. By controlling the
injection time of ethanol, the particle growth could be
quenched by ethanol-induced crystallization from amorphous
particles to ZIF-8 crystals. The particle size of the biocomposite
was tuned in the 40–100 nm range by varying residence time
prior to introduction of ethanol. As a proof-of-concept, this
procedure was used for the encapsulation of AAT in ZIF-8.
Upon release of the biotherapeutic from the composite, the
trypsin inhibitor function of AAT was preserved.
Metal–organic frameworks (MOFs) are a class of extended
materials that are composed of inorganic nodes coordinated
by multi-topic organic ligands.[1] Recently, different MOF-
based biocomposites have been studied for applications in
drug-delivery, bio-banking and biocatalysis.[2–4] Among the
different MOFs explored for biotechnology and biomedicine,
zeolitic imidazolate framework 8 (ZIF-8) has been exten-
sively studied as its components can self-assemble around
bioentities, under biocompatible conditions, to form a protec-
tive crystalline coating.[5–7] Typically, ZIF-8 biocomposites are
synthesized by mixing selected biomacromolecules and the
ZIF precursors (2-methylimidazole, HmIM, and Zn2+) in
water.[3] By varying the concentration and molar ratios of ZIF
precursors and protein, a number of different structure phases
can be prepared (for example, sod, dia, kat, ZIF-C).[8,9] The
most extensively investigated topology is sodalite (sod)[10] as it
has been shown to afford crystalline microporous materials
that can protect encapsulated proteins from inhospitable
environments.[5–7, 11, 12] Furthermore, the sod ZIF-8 coating can
be degraded under mild conditions (mild acidic conditions,
phosphate ions or chelating agents) allowing for triggered
release of the encapsulated biomolecule with retention of its
native activity.[13,14]
To advance research of ZIF-8 biocomposites for applica-
tion to biomedicine, such as drug delivery, there is a need for
the larger scale production of particles with controlled
size.[15–17] For example, a number of studies have highlighted
how the dimensions of nanoparticle-based systems can
influence blood-circulation time, cellular uptake and mech-
anism of internalization.[15]
In recent years, flow chemistry has become established as
an effective technology for the scalable synthesis of fine
chemicals, active pharmaceutical ingredients, and functional
materials.[18, 19] Enhanced and scale-independent heat transfer
and mass transfer allow straightforward scalability by, for
example, lengthening the processing time. Another key
advantage of flow processing is that precise and reproducible
access to well-defined (typically very short) reaction times can
be achieved by varying the respective reactor volumes or flow
rates.[20, 21] Recently, it has been demonstrated that MOFs can
be prepared with controlled particle size using flow technol-
ogy.[22–28] Specifically, ZIF-8 has been produced in flow using
a variety of equipment and procedures.[29–32] However, the
concept of tuning particle size by controlling residence time
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prior to ethanol-induced crystallization has not been reported
for any MOF. Furthermore, the preparation of biomacromo-
lecules@ZIF-8 in flow has not been described before.
Herein, we show that flow synthesis can be used as
a scalable method to prepare BSA@ZIF-8 with controlled
particle size in the 40 to 100 nm range, by modifying the
residence time prior quenching with ethanol. This procedure
was applied to the synthesis of a ZIF-8-based composite of
a clinical biotherapeutic (protease inhibitor a1-antitrypsin,
AAT) with a size suitable for intravenous drug delivery
applications.[15] Further, we released AAT from the ZIF-8
host and showed that bioactivity was preserved.
To develop a continuous flow procedure and to under-
stand the growth kinetics for ZIF-8 based composites we used
BSA as model protein (Supporting Information, Section S2.1,
4).[5,8, 33, 34] The nucleation and growth of BSA@ZIF-8 was
examined by a synchrotron time-resolved SAXS study using
a stopped-flow set-up (Supporting Information, Sections S2,
S3). Injection of the Zn(OAc)2 and BSA-HmIM solutions
triggered the acquisition system of rapid SAXS data collec-
tion with a time resolution of 100 ms. The quantity Q̃
(Supporting Information, Section S2.1), related to the invar-
iant of the scattering curve and sensitive to changes in
particles volume fraction and electron density contrast,
increased during the first 3 min. This is attributed to rapid
growth of amorphous particles with dimension larger than the
set-up resolution limit (> 35 nm, qmin = 0.1 nm
1 thus no
Guinier regime and no diffraction peaks were detected;
Figure 1; Supporting Information, Figure S7).[35] The amor-
phous particles are composed by BSA and by HmIM
coordinated to Zn2+, as determined via FTIR[36] (Supporting
Information, Figure S9). After 3 min, the (110) diffraction
peak of ZIF-8 was observed, and its increase in intensity was
accompanied by a decrease of Q̃ (Figure 1a). This trend can
be explained by the conversion of amorphous particles (high
density) into ZIF-8 crystals (low density),[37, 38] resulting in the
overall reduction of Q̃.[39] Bustamante et al. demonstrated
that alcoholic solvents facilitate the crystallization of ZIF-8.[40]
We hypothesized that the rapid injection of ethanol could
quench the growth of amorphous particles and engender
crystallization of ZIF-8. To examine the role of ethanol in
ZIF-8 crystallization, in the stopped-flow set-up we mixed
aqueous solutions of BSA/HmIM and Zn2+ and then, after
19 ms, we added an equal volume of ethanol.
After 2 s from the injection of ethanol, the (110)
diffraction peak of sod-ZIF-8 was detected (Figure 1b;
Supporting Information, Figure S8). The integrated intensity
of this peak over time is plotted in Figure 1b, and shows that
a plateau is reached after 35 s. We note that the observation of
the 110 reflection was 90 times faster than neat water. The
average crystallite size obtained from the ethanol quench was
17 nm while the non-quenched synthesis yields crystallites
larger than 200 nm. These data suggest that ethanol both
triggers the crystallization of BSA@ZIF-8 biocomposites and
quenches the particle growth.
Further, we used a simple microfluidic setup composed of
Y- and T-mixers (Figure 2a; Supporting Information, Sec-
tions S2.2, S5) to ensure that replication of biocomposite
synthesis could be achieved without the need for specialized
equipment. This continuous flow set-up was initially used to
study the influence of the ethanol/water flow rate ratio on the
crystal size, we fixed the residence time to 0.33 s and varied
the flow rate of ethanol (Supporting Information Section 5.5).
The trend is reported in Figure 2b (Supporting Information,
Table S2) and shows that a higher ethanol flow rate results in
smaller sod crystallites, with a minimum size of ca. 50 nm
(Figure 2b; Supporting Information, Table S2). We examined
the crystal sizes by scanning electron microscopy (SEM;
Supporting Information, Figures S18, S19), and for the high-
est ethanol/water ratio (that is, 1.6) we observed a broader
particle size distribution. Accordingly, we decided to use a 1:1
flow rate ratio for a better control over the particle size
distribution. Other quenching methods (for example, crystal
modulators,[41] 1-methyl imidazole,[42] Supporting Informa-
tion, Sections 5.2, 5.3) were also examined, but were found to
be comparatively ineffective.
Next, we examined the influence of the residence time
when using a 1:1 ethanol/water ratio. The prepared biocom-
posites were studied by atomic force microscopy (AFM) and
SEM (Figure 2 c; Supporting Information, Section S6). By
varying the residence time from 0.33 to 120 s we could
synthesize BSA@ZIF-8 crystals with particle sizes ranging
from 40 to 100 nm. The AFM data were fitted with a power
law that can predict the required residence time to obtain
particles of a desired size (Figure 2c; Supporting Information,
Section 6). For selected samples (residence times = 0.33 s, 30 s
and 120 s for samples B1, B2 and B3, respectively), we further
investigated the structural and physicochemical properties of
the biocomposites. X-ray diffraction (XRD) confirmed the
sod topology of ZIF-8 for all measured samples (Figure 3a;
Supporting Information, Figure S23). Moreover, the crystal-
lite size calculated from (110) diffraction peak of ZIF-8 (37,
59, and 95 nm for samples B1, B2, and B3, respectively;
Figure 1. a) Time evolution of the integrated intensity of the (110)
reflection of ZIF-8 (I(110)) and of Q̃ (0.1–0.7 nm1 range) calculated
from time-resolved SAXS synthesis of BSA@ZIF-8 in water. b) Time
evolution of the integrated intensity of the (110) diffraction peak of sod
ZIF-8 (I(110)) during the first 50 s of the synthesis of BSA@ZIF-8 in
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Supporting Information, Table S3) are in agreement with the
particle size calculated from their AFM micrographs, suggest-
ing the formation of single crystal particles of BSA@ZIF-8.
Additionally, N2 sorption isotherms at 77 K confirmed the
presence of permanent microporosity and a dependence of
the gate opening pressure on the particle size (Supporting
Information, Figure S24).[30, 43] After washing with water,
ethanol, and SDS[8] (Supporting Information, Section 4.1),
the encapsulation of BSA was confirmed via Fourier trans-
form infrared (FTIR) spectroscopy, which show the charac-
teristic BSA bands (for example, amide I at 1700-1610 cm1
and amide II at 1595-1480 cm1; Figure 3b; Supporting Infor-
mation, Figure S23) in addition to the typical fingerprint of
sod ZIF-8.[44, 45] Finally, the loading of BSA for samples B1, B2
and B3 was determined to be 5.1 0.6, 5.2 0.6 and 5.8
0.4 wt %, respectively, by ICP-MS (Supporting Information,
Table S4).
To demonstrate the scalability of the method, we synthe-
sized BSA@ZIF-8 with average particle size of 60 nm in
continuous flow for 5 h (Supporting Information Section 8).
During this time the calculated standard deviation of the
average particle size was only 3 nm; the measured produc-
tivity was 2.1 gh1, a value that is comparable with the flow
preparation of pure MOFs on lab scale.[26] Next, we studied
the long-term stability of BSA@ZIF-8 in the stock solution
(as collected from the flow set-up) by AFM. In this case we
selected the smaller particles as they are typically less stable
than larger particles;[46,47] our analysis demonstrated that the
particle size distribution remained unchanged over a two-
week period (Supporting Information, Section S6.1).
We applied the procedure developed for BSA@ZIF-8 to
synthesize biocomposites of a1-antitrypsin, AAT. AAT is
a member of the serine protease inhibitor (serpin) super-
family and is currently under investigation as a biotherapeutic
for the treatment of several neutrophilic diseases, for the
control of inflammatory, immunological, and tissue-protec-
tive responses.[48–52] Three different samples were synthesized
using the flow setup, employing the residence times used for
the preparation of BSA@ZIF-8 biocomposites (Supporting
Information, Section S7). The crystallite sizes calculated from
the (110) diffraction peak for the different samples (Support-
ing Information, Figure S27; 40, 59, and 87 nm for samples
A1, A2, and A3, respectively) are analogous to those
calculated for the BSA@ZIF-8 samples. However, the particle
sizes measured by AFM (Supporting Information, Fig-
ure S26; A1 = 93 nm, A2 = 109 nm, A3 = 179 nm) are larger
than the particle size observed for BSA (B1 = 46 nm, B2 =
67 nm, B3 = 99 nm). This could be explained by the formation
Figure 2. a) View of the microfluidic setup, where the residence time
prior quenching can be varied by changing the length of the reactor or
flow rates. b) Average crystallite size of BSA@ZIF-8 obtained, versus
the ethanol flow rate employed. The red line is the fitted exponential
decay (crystallite size = a +b*ex/t, with a =533, b =22030,
t = 0.60.1, x = flow rate ratio, R2 =0.98). c) Average particle size
obtained from AFM topography as a function of the residence time,
including a power law fit of the experimental data (particle
size = a + b*xc, with a = 453, b = 31, c = 0.60.1, x = residence
time, R2 = 0.97).
Figure 3. XRD patterns a) of BSA@ZIF-8 synthesized in batch and in
flow (B1, B2, B3). FTIR spectra b) of BSA@ZIF-8 synthesized in batch
and in flow (B1, B2, B3) and of ZIF-8 and BSA.
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of crystalline clusters suggesting that that the type of proteins
influences the structure of the final biocomposite.[5] The
encapsulation of AAT was confirmed by the presence of
amide I and amide II bands (Supporting Information, Fig-
ure S27) via FTIR spectroscopy.[44] The loading of AAT for
samples A1, A2, and A3 was determined to be 4.2 0.3, 4.1
0.7, and 3.1 0.6 wt % by ICP-MS (Supporting Information,
Table S6).
To ascertain whether the flow chemistry procedure (that
is, ethanol quench)[53] and the ZIF-8 chemical environment[54]
affect the AAT protein structure (that is, denaturation) we
studied the activity of the released bio therapeutic.[55] Thus,
the ZIF matrix of AAT@ZIF-8 was dissolved in 1 mm HCl
and the released AAT exposed to a trypsin solution and
incubated at 4 8C for 30 min. Then, the protease activity of
trypsin was evaluated using a standard colorimetric assay
(Supporting Information, Section S2.1). Importantly, the
resulting data confirmed that the released AAT was success-
fully inhibiting protease, and, thus remains active after release
from the ZIF matrix (Figure 4).[55] Additionally, when
AAT@ZIF-8 crystals were exposed to trypsin at pH 7.0, the
proteolytic activity was fully retained (Supporting Informa-
tion, Figure S29). These results confirmed that AAT is
encapsulated within the ZIF-8 particles and the inhibition of
trypsin occurs only when AAT is released from the MOF
biocomposite. In general, as ethanol can denature some
proteins,[53, 56] the compatibility of each specific biomacromo-
lecule with the quenching agent should be examined.
In conclusion, we report the first synthesis of ZIF-8-based
biocomposites with sodalite topology in continuous flow. By
using a simple experimental setup, the particle size can be
precisely tuned by controlling the residence time prior to
injection of ethanol to the mixed ZIF precursor solution.
Owing to the abrupt amorphous-to-crystalline transition, an
ethanol quenching method was used to adjust the particle
dimensions in the 40–100 nm range. The general study was
performed using BSA as model protein and we demonstrated
that 60 nm BSA@ZIF-8 particles could be continuously
prepared for 5 h. Then we applied the flow system to test
for the encapsulation of AAT, a biotherapeutic with anti-
inflammatory and immunomodulatory properties.
AAT@ZIF-8 samples with 90, 110 and 180 nm were prepared
and after dissolution of the ZIF matrix, the protease inhibitor
fully retained its bioactivity. The continuous flow synthesis of
ZIF-8-based composites afforded a control over the particle
size that is suitable for intravenous drug delivery adminis-
tration (particle size  200 nm). We believe that this synthetic
method will facilitate the application of biotherapeutic@ZIF-
8 for biomedicine. It is anticipated that the precise control
over the particle dimension and topology could also expedite
the use of enzyme@ZIF-8 for biocatalytic applications.
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